Ascendis Pharma AS (ASND) earnings
In the quarter ended December 2025, Ascendis Pharma AS had revenue of 248M EUR, up 42.3% on a year earlier.
On August 13, 2026 it reported EPS of 3.29 against an estimate of 0.78 (beat).
The next report is expected on Wednesday, November 11, 2026, with EPS expected around 1.13.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Wed Nov 11, 2026 | — | 1.13 | — |
| Last | Thu Aug 13, 2026 | — | 0.78 | 3.29 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Ascendis Pharma AS's 10-Q and 10-K filings with the SEC, in EUR. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | 248M EUR | +42.3% | — | — | 4.0% | 2026-02-11 |
| Sep 30, 2025 | 214M EUR | +269.4% | -1.00 | — | 5.1% | 2025-11-12 |
| Jun 30, 2025 | 158M EUR | +339.0% | -0.64 | — | -33.5% | 2025-08-07 |
| Mar 31, 2025 | 101M EUR | +5.3% | -1.58 | — | -103.2% | 2025-05-01 |
| Dec 31, 2024 | 174M EUR | +26.3% | — | — | 0.2% | 2025-02-12 |
| Sep 30, 2024 | 58M EUR | +20.4% | -1.72 | — | -167.3% | 2024-11-14 |
| Jun 30, 2024 | 36M EUR | -24.0% | -1.91 | — | -370.2% | 2024-09-03 |
| Mar 31, 2024 | 96M EUR | +185.5% | -2.30 | — | -51.2% | 2024-05-02 |
| Dec 31, 2023 | 138M EUR | +501.4% | — | — | -26.6% | 2024-02-07 |
| Sep 30, 2023 | 48M EUR | +214.2% | -2.88 | — | -279.8% | 2023-11-07 |
| Jun 30, 2023 | 47M EUR | +669.4% | -2.16 | — | -297.2% | 2023-09-05 |
| Mar 31, 2023 | 34M EUR | +391.9% | -1.98 | — | -427.8% | 2023-04-27 |
Questions
When does Ascendis Pharma AS report earnings?
Ascendis Pharma AS's next earnings report is expected on November 11, 2026.
How did Ascendis Pharma AS do last quarter?
In the quarter ended December 2025, Ascendis Pharma AS had revenue of 248M EUR, up 42.3% on a year earlier.
From Ascendis Pharma AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.